Clinical Guidelines

Over the last 50 years, revascularization and pharmacotherapeutic innovations have led to significant reductions in major adverse CV events associated with both acute and chronic coronary diseases.

Semaglutide 2.4 mg improved symptoms and physical function in patients with obesity-related heart failure with preserved ejection fraction compared with placebo, regardless of diuretic use, according to new data from the STEP-HFpEF trials.

Experts say that the management of Q fever, a zoonotic disease caused by Coxiella burnetii, is complicated by the lack of clinical guidance on screening protocols, treatment regimens and durations.

A new guideline on lower-extremity peripheral artery disease encouraged managing care with a multispecialty team and having patients undergo structured exercise programs.

A new guideline on hypertrophic cardiomyopathy endorses the use of cardiac myosin inhibitors for certain patients with obstructive HCM and encourages exercise in all patients with HCM.

BOSTON — New recommendations from ACP on type 2 diabetes treatment include adding a GLP-1 agonist or SGLT-2 inhibitor to therapy for patients who have inadequate glycemic control, the organization announced.

BOSTON — The ACP has been designated as a GRADE Center based on its developmental processes for guidelines, becoming the first organization in the U.S to receive such a designation.